Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review

References

• Abrahams, K. A., & Besra, G. S. (2018). Mycobacterial cell wall biosynthesis: A multifaceted antibiotic target. Parasitology, 145(2), 116–133. https://doi.org/10.1017/S0031182016002377
   PubMed Web of Science ®Google Scholar
• Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., Becerra, M. C., Benedetti, A., Burgos, M., Centis, R., Chan, E. D., Chiang, C.-Y., Cox, H., D'Ambrosio, L., DeRiemer, K., Dung, N. H., Enarson, D., Falzon, D., Flanagan, K., … Yew, W. W. (2012). Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. PLoS Medicine, 9(9). https://doi.org/10.1371/journal.pmed.1001300
   PubMedGoogle Scholar
• Alderwick, L. J., Harrison, J., Lloyd, G. S., & Birch, H. L. (2015). The mycobacterial cell wall—Peptidoglycan and Arabinogalactan. Cold Spring Harbor Perspectives in Medicine, 5(8), a021113. https://doi.org/10.1101/CSHPERSPECT.A021113
   PubMed Web of Science ®Google Scholar
• Amado, P. S. M., Woodley, C., Cristiano, M. L. S., & O'Neill, P. M. (2022). Recent advances of DprE1 inhibitors against Mycobacterium tuberculosis: Computational analysis of physicochemical and ADMET properties. ACS Omega, 7(45), 40659–40681. https://doi.org/10.1021/ACSOMEGA.2C05307/SUPPL_FILE/AO2C05307_SI_001.XLSX
   PubMedGoogle Scholar
• Balabon, O., Pitta, E., Rogacki, M. K., Meiler, E., Casanueva, R., Guijarro, L., Huss, S., Lopez-Roman, E. M., Santos-Villarejo, Á., Augustyns, K., Ballell, L., Aguirre, D. B., Bates, R. H., Cunningham, F., Cacho, M., & Van Der Veken, P. (2020). Optimization of hydantoins as potent antimycobacterial decaprenylphosphoryl-β-d-ribose oxidase (DprE1) inhibitors. Journal of Medicinal Chemistry, 63(10), 5367–5386. https://doi.org/10.1021/acs.jmedchem.0c00107
   PubMed Web of Science ®Google Scholar
• Bansal, R., Sharma, D., & Singh, R. (2017). Tuberculosis and its treatment: An overview. Mini-Reviews in Medicinal Chemistry, 18(1), 58-71. https://doi.org/10.2174/1389557516666160823160010
   Web of Science ®Google Scholar
• Batt, S. M., Cacho Izquierdo, M., Castro Pichel, J., Stubbs, C. J., Vela-Glez Del Peral, L., Pérez-Herrán, E., Dhar, N., Mouzon, B., Rees, M., Hutchinson, J. P., Young, R. J., McKinney, J. D., Barros Aguirre, D., Ballell, L., Besra, G. S., & Argyrou, A. (2015). Whole cell target engagement identifies novel inhibitors of Mycobacterium tuberculosis decaprenylphosphoryl-β- d -ribose oxidase. ACS Infectious Diseases, 1(12), 615–626. https://doi.org/10.1021/acsinfecdis.5b00065
   PubMed Web of Science ®Google Scholar
• Batt, S. M., Jabeen, T., Bhowruth, V., Quill, L., Lund, P. A., Eggeling, L., Alderwick, L. J., Fütterer, K., & Besra, G. S. (2012). Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 109(28), 11354–11359. https://www.pnas.org/content/109/28/11354 https://doi.org/10.1073/pnas.1205735109
   PubMed Web of Science ®Google Scholar
• Bedaquiline, Pretomanid, and Linezolid (BPaL) | TB |CDC. (n.d). Retrieved May 15, 2023, from https://www.cdc.gov/tb/topic/drtb/bpal/default.htm
   Google Scholar
• Bhutani, I., Loharch, S., Gupta, P., Madathil, R., & P, R. (2015). Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies. PloS One, 10(3), e0119771. https://doi.org/10.1371/JOURNAL.PONE.0119771
   PubMed Web of Science ®Google Scholar
• Bonde, C., Gawad, J., & Bonde, S. (2022). Insights into development of Decaprenyl-phosphoryl-β-D-ribose 2′-epimerase (DprE1) inhibitors as antitubercular agents: A state of the art review. Indian Journal of Tuberculosis, 69(4), 404–420. https://doi.org/10.1016/j.ijtb.2021.09.003
   PubMedGoogle Scholar
• Borthwick, J. A., Alemparte, C., Wall, I., Whitehurst, B. C., Argyrou, A., Burley, G., De Dios-Anton, P., Guijarro, L., Monteiro, M. C., Ortega, F., Suckling, C. J., Pichel, J. C., Cacho, M., & Young, R. J. (2020). Mycobacterium tuberculosis decaprenylphosphoryl-β- d -ribose oxidase inhibitors: Expeditious reconstruction of suboptimal hits into a series with potent in vivo activity. Journal of Medicinal Chemistry, 63(5), 2557–2576. https://doi.org/10.1021/ACS.JMEDCHEM.9B01561/SUPPL_FILE/JM9B01561_SI_001.CSV
   PubMed Web of Science ®Google Scholar
• Brecik, M.,Centárová, I.,Mukherjee, R.,Kolly, G. S.,Huszár, S.,Bobovská, A.,Kilacsková, E.,Mokošová, V.,Svetlíková, Z.,Šarkan, M.,Neres, J.,Korduláková, J.,Cole, S. T., &Mikušová, K. (2015). DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization. ACS Chemical Biology, 10(7), 1631–1636. https://doi.org/10.1021/acschembio.5b0023725906160
   PubMed Web of Science ®Google Scholar
• Brennan, P., & Crick, D. (2007). The cell-wall core of Mycobacterium tuberculosis in the context of drug discovery. Current Topics in Medicinal Chemistry, 7(5), 475–488. https://doi.org/10.2174/156802607780059763
   PubMed Web of Science ®Google Scholar
• Bruchfeld, J., Correia-Neves, M., & Kallenius, G. (2015). Tuberculosis and HIV coinfection. Cold Spring Harbor Perspectives in Medicine, 5(7), a017871. https://doi.org/10.1101/CSHPERSPECT.A017871
   PubMed Web of Science ®Google Scholar
• BTZ-043 | Working Group for New TB Drugs. (n.d). Retrieved February 27, 2022, from https://www.newtbdrugs.org/pipeline/compound/btz-043
   Google Scholar
• Buroni, S., Pasca, M. R., De Jesus Lopes Ribeiro, A. L., Degiacomi, G., Molteni, E., & Riccardi, G. (2012). Antituberculars which target decaprenylphosphoryl-β-Dribofuranose 2′-oxidase DprE1: State of art. Applied Microbiology and Biotechnology, 94(4), 907–916. https://doi.org/10.1007/s00253-012-4013-4
   PubMed Web of Science ®Google Scholar
• Caminero, J. A., García-Basteiro, A. L., & Rendon, A. (2019). Multidrug-resistant tuberculosis. The Lancet, 394(10195), 298. https://doi.org/10.1016/S0140-6736(19)30696-8
   PubMedGoogle Scholar
• Campaniço, A., Moreira, R., & Lopes, F. (2018). Drug discovery in tuberculosis. New drug targets and antimycobacterial agents. European Journal of Medicinal Chemistry, 150, 525–545. https://doi.org/10.1016/J.EJMECH.2018.03.020
   PubMed Web of Science ®Google Scholar
• Campbell, I. A., & Bah-Sow, O. (2006). Pulmonary tuberculosis: Diagnosis and treatment. BMJ (Clinical Research ed.), 332(7551), 1194–1197. https://doi.org/10.1136/BMJ.332.7551.1194
   PubMedGoogle Scholar
• Chatterji, M., Shandil, R., Manjunatha, M. R., Solapure, S., Ramachandran, V., Kumar, N., Saralaya, R., Panduga, V., Reddy, J., Prabhakar, K. R., Sharma, S., Sadler, C., Cooper, C. B., Mdluli, K., Iyer, P. S., Narayanan, S., & Shirude, P. S. (2014). 1,4-azaindole, a potential drug candidate for treatment of tuberculosis. Antimicrobial Agents and Chemotherapy, 58(9), 5325–5331. https://doi.org/10.1128/AAC.03233-14
   PubMed Web of Science ®Google Scholar
• Chhabra, S., Kumar, S., & Parkesh, R. (2021). Chemical space exploration of DprE1 inhibitors using chemoinformatics and artificial intelligence. ACS Omega, 6(22), 14430–14441. https://doi.org/10.1021/acsomega.1c01314
   PubMed Web of Science ®Google Scholar
• Chiaradia, L., Lefebvre, C., Parra, J., Marcoux, J., Burlet-Schiltz, O., Etienne, G., Tropis, M., & Daffé, M. (2017). Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane. Scientific Reports, 7(1), 1–12. https://doi.org/10.1038/s41598-017-12718-4
   PubMedGoogle Scholar
• Chikhale, R. V., Barmade, M. A., Murumkar, P. R., & Yadav, M. R. (2018). Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis. Journal of Medicinal Chemistry, 61(19), 8563–8593. https://doi.org/10.1021/ACS.JMEDCHEM.8B00281/ASSET/IMAGES/LARGE/JM-2018-00281W_0015.JPEG
   PubMed Web of Science ®Google Scholar
• Chikhale, R., Menghani, S., Babu, R., Bansode, R., Bhargavi, G., Karodia, N., Rajasekharan, M. V., Paradkar, A., & Khedekar, P. (2015). Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides. European Journal of Medicinal Chemistry, 96, 30–46. https://doi.org/10.1016/j.ejmech.2015.04.011
   PubMed Web of Science ®Google Scholar
• Christophe, T., Jackson, M., Jeon, H. K., Fenistein, D., Contreras-Dominguez, M., Kim, J., Genovesio, A., Carralot, J.-P., Ewann, F., Kim, E. H., Lee, S. Y., Kang, S., Seo, M. J., Park, E. J., Škovierová, H., Pham, H., Riccardi, G., Nam, J. Y., Marsollier, L., … Brodin, P. (2009). High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathogens, 5(10), e1000645. https://doi.org/10.1371/journal.ppat.1000645
   PubMed Web of Science ®Google Scholar
• Cole, S. T., & Riccardi, G. (2011). New tuberculosis drugs on the horizon. Current Opinion in Microbiology, 14(5), 570–576. https://doi.org/10.1016/j.mib.2011.07.022
   PubMed Web of Science ®Google Scholar
• Degiacomi, G., Belardinelli, J. M., Pasca, M. R., Rossi, E. D., Riccardi, G., & Chiarelli, L. R. (2020). Promiscuous targets for antitubercular drug discovery: The paradigm of DprE1 and MmpL3. Applied Sciences, 10(2), 623. https://doi.org/10.3390/app10020623
   Google Scholar
• Dhiman, R., &Singh, R. (2018). Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis. IUBMB Life, 70(9), 905–916. https://doi.org/10.1002/iub.186329761628
   PubMed Web of Science ®Google Scholar
• Fan, D., Wang, B., Stelitano, G., Savková, K., Shi, R., Huszár, S., Han, Q., Mikušová, K., Chiarelli, L. R., Lu, Y., & Qiao, C. (2021). Structural and activity relationships of 6-sulfonyl-8-nitrobenzothiazinones as antitubercular agents. Journal of Medicinal Chemistry, 64(19), 14526–14539. https://doi.org/10.1021/ACS.JMEDCHEM.1C01049/SUPPL_FILE/JM1C01049_SI_002.CSV
   PubMed Web of Science ®Google Scholar
• Frieden, T. R., & Munsiff, S. S. (2005). The DOTS strategy for controlling the global tuberculosis epidemic. Clinics in Chest Medicine, 26(2), 197–205, v. https://doi.org/10.1016/J.CCM.2005.02.001
   PubMed Web of Science ®Google Scholar
• Gao, C., Ye, T. H., Wang, N. Y., Zeng, X. X., Zhang, L. D., Xiong, Y., You, X. Y., Xia, Y., Xu, Y., Peng, C. T., Zuo, W. Q., Wei, Y., & Yu, L. T. (2013). Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents. Bioorganic & Medicinal Chemistry Letters, 23(17), 4919–4922. https://doi.org/10.1016/J.BMCL.2013.06.069
   PubMed Web of Science ®Google Scholar
• Global Tuberculosis Programme. (n.d). Retrieved November 25, 2021, from https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy
   Google Scholar
• Global Tuberculosis Report 2021. (n.d). Retrieved November 10, 2021, from https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021
   Google Scholar
• Global Tuberculosis Report 2022. (n.d). Retrieved January 18, 2023, from https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
   Google Scholar
• Gygli, S. M., Borrell, S., Trauner, A., & Gagneux, S. (2017). Antimicrobial resistance in Mycobacterium tuberculosis: Mechanistic and evolutionary perspectives. FEMS Microbiology Reviews, 41(3), 354–373. https://doi.org/10.1093/FEMSRE/FUX011
   PubMed Web of Science ®Google Scholar
• Hariguchi, N., Chen, X., Hayashi, Y., Kawano, Y., Fujiwara, M., Matsuba, M., Shimizu, H., Ohba, Y., Nakamura, I., Kitamoto, R., Shinohara, T., Uematsu, Y., Ishikawa, S., Itotani, M., Haraguchi, Y., Takemura, I., & Matsumoto, M. (2020). OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DprE1 inhibitor. Antimicrobial Agents and Chemotherapy, 64(6), e02020-19. https://doi.org/10.1128/AAC.02020-19
   PubMed Web of Science ®Google Scholar
• Hu, X. P., Yang, L., Chai, X., Lei, Y. X., Alam, M. S., Liu, L., Shen, C., Jiang, D. J., Wang, Z., Liu, Z. Y., Xu, L., Wan, K. L., Zhang, T. Y., Yin, Y. L., Li, D., Cao, D. S., & Hou, T. J. (2022). Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening. Acta Pharmacologica Sinica, 43(6), 1605–1615. https://doi.org/10.1038/s41401-021-00779-1
   PubMed Web of Science ®Google Scholar
• Imran, M., Alshrari, A. S., Thabet, H. K., Abida, & Bakht, M. A. (2021). Synthetic molecules as DprE1 inhibitors: A patent review.Expert Opinion on Therapeutic Patents, 31(8), 759–772. https://doi.org/10.1080/13543776.2021.1902990
   PubMed Web of Science ®Google Scholar
• Incandela, M. L., Perrin, E., Fondi, M., de Jesus Lopes Ribeiro, A. L., Mori, G., Moiana, A., Gramegna, M., Fani, R., Riccardi, G., & Pasca, M. R. (2013). DprE1, a new taxonomic marker in mycobacteria. FEMS Microbiology Letters, 348(1), 66–73. https://doi.org/10.1111/1574-6968.12246
   PubMed Web of Science ®Google Scholar
• Jadhavar, P., Vaja, M., Dhameliya, T., & Chakraborti, A. (2015). Oxazolidinones as anti-tubercular agents: Discovery, development and future perspectives. Current Medicinal Chemistry, 22(38), 4379–4397. https://doi.org/10.2174/0929867323666151106125759
   PubMed Web of Science ®Google Scholar
• Keam, S. J. (2019). Pretomanid: First approval. Drugs, 79(16), 1797–1803. https://doi.org/10.1007/S40265-019-01207-9
   PubMed Web of Science ®Google Scholar
• Kiazyk, S., & Ball, T. (2017). Tuberculosis (TB): Latent tuberculosis infection: An overview. Canada Communicable Disease Report = Releve Des Maladies Transmissibles au Canada, 43(3-4), 62–66. https://doi.org/10.14745/CCDR.V43I34A01
   PubMedGoogle Scholar
• Kumar, A., Rajappan, R., Kini, S. G., Rathi, E., Dharmarajan, S., & Sreedhara Ranganath Pai, K. (2021). e-Pharmacophore model-guided design of potential DprE1 inhibitors: Synthesis, in vitro antitubercular assay and molecular modelling studies. Chemical Papers, 75(10), 5571–5585. https://doi.org/10.1007/s11696-021-01743-3
   Web of Science ®Google Scholar
• Kwan, C. K., & Ernst, J. D. (2011). HIV and tuberculosis: A deadly human syndemic. Clinical Microbiology Reviews, 24(2), 351–376. https://doi.org/10.1128/CMR.00042-10
   PubMed Web of Science ®Google Scholar
• Lamichhane, G. (2011). Novel targets in M. tuberculosis: Search for new drugs. Trends in Molecular Medicine, 17(1), 25–33. https://doi.org/10.1016/J.MOLMED.2010.10.004
   PubMed Web of Science ®Google Scholar
• Landge, S., Mullick, A. B., Nagalapur, K., Neres, J., Subbulakshmi, V., Murugan, K., Ghosh, A., Sadler, C., Fellows, M. D., Humnabadkar, V., Mahadevaswamy, J., Vachaspati, P., Sharma, S., Kaur, P., Mallya, M., Rudrapatna, S., Awasthy, D., Sambandamurthy, V. K., Pojer, F., … Ramachandran, V. (2015). Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose 2′-oxidase. Bioorganic & Medicinal Chemistry, 23(24), 7694–7710. https://doi.org/10.1016/j.bmc.2015.11.017
   PubMed Web of Science ®Google Scholar
• Li, P., Guo, K., Fu, L., Wang, B., Zhang, B., Gong, N., Lu, Y., Ma, C., Huang, H., Lu, Y., & Li, G. (2023). Solubility-driven optimization of benzothiopyranone salts leading to a preclinical candidate with improved pharmacokinetic properties and activity against Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 246, 114993. https://doi.org/10.1016/J.EJMECH.2022.114993
   PubMed Web of Science ®Google Scholar
• Liu, J., Dai, H., Wang, B., Liu, H., Tian, Z., & Zhang, Y. (2022). Exploring disordered loops in DprE1 provides a functional site to combat drug-resistance in Mycobacterium strains. European Journal of Medicinal Chemistry, 227, 113932. https://doi.org/10.1016/J.EJMECH.2021.113932
   PubMed Web of Science ®Google Scholar
• Liu, L., Kong, C., Fumagalli, M., Savková, K., Xu, Y., Huszár, S., Sammartino, J. C., Fan, D., Chiarelli, L. R., Mikušová, K., Sun, Z., & Qiao, C. (2020). Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents. European Journal of Medicinal Chemistry, 208, 112773. https://doi.org/10.1016/J.EJMECH.2020.112773
   PubMed Web of Science ®Google Scholar
• Liu, R., Lyu, X., Batt, S. M., Hsu, M.-H., Harbut, M. B., Vilchèze, C., Cheng, B., Ajayi, K., Yang, B., Yang, Y., Guo, H., Lin, C., Gan, F., Wang, C., Franzblau, S. G., Jacobs, W. R., Besra, G. S., Johnson, E. F., Petrassi, M., … Wang, F. (2017). Determinants of the inhibition of DprE1 and CYP2C9 by antitubercular thiophenes. Angewandte Chemie (International ed. in English), 56(42), 13011–13015. https://doi.org/10.1002/anie.201707324
   PubMed Web of Science ®Google Scholar
• Li, P., Wang, B., Zhang, X., Batt, S. M., Besra, G. S., Zhang, T., Ma, C., Zhang, D., Lin, Z., Li, G., Huang, H., & Lu, Y. (2018). Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones. European Journal of Medicinal Chemistry, 160, 157–170. https://doi.org/10.1016/J.EJMECH.2018.09.042
   PubMed Web of Science ®Google Scholar
• Lv, K., Tao, Z., Liu, Q., Yang, L., Wang, B., Wu, S., Wang, A., Huang, M., Liu, M., & Lu, Y. (2018). Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety. European Journal of Medicinal Chemistry, 151, 1–8. https://doi.org/10.1016/J.EJMECH.2018.03.060
   PubMed Web of Science ®Google Scholar
• Lv, K., You, X., Wang, B., Wei, Z., Chai, Y., Wang, B., Wang, A., Huang, G., Liu, M., & Lu, Y. (2017). Identification of better pharmacokinetic benzothiazinone derivatives as new antitubercular agents. ACS Medicinal Chemistry Letters, 8(6), 636–641. https://doi.org/10.1021/ACSMEDCHEMLETT.7B00106/SUPPL_FILE/ML7B00106_SI_001.PDF
   PubMed Web of Science ®Google Scholar
• Macozinone (MCZ, PBTZ-169). (n.d). | Working Group for New TB Drugs. Retrieved February 27, 2022, from https://www.newtbdrugs.org/pipeline/compound/macozinone-mcz-pbtz-169
   Google Scholar
• Magnet, S., Hartkoorn, R. C., Székely, R., Pató, J., Triccas, J. A., Schneider, P., Szántai-Kis, C., Rfi, L., Chambon, M., Banfi, D., Bueno, M., Turcatti, G., Kéri, G., & Cole, S. T. (2010). Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinburgh, Scotland), 90(6), 354–360. https://doi.org/10.1016/j.tube.2010.09.001
   PubMed Web of Science ®Google Scholar
• Mahajan, R. (2013). Bedaquiline: First FDA-approved tuberculosis drug in 40 years. International Journal of Applied and Basic Medical Research, 3(1), 1. https://doi.org/10.4103/2229-516X.112228
   PubMedGoogle Scholar
• Maitra, A., Munshi, T., Healy, J., Martin, L. T., Vollmer, W., Keep, N. H., & Bhakta, S. (2019). Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles’ heel for the TB-causing pathogen. FEMS Microbiology Reviews, 43(5), 548–575. https://doi.org/10.1093/FEMSRE/FUZ016
   PubMed Web of Science ®Google Scholar
• Makarov, V., Lechartier, B., Zhang, M., Neres, J., van der Sar, A. M., Raadsen, S. A., Hartkoorn, R. C., Ryabova, O. B., Vocat, A., Decosterd, L. A., Widmer, N., Buclin, T., Bitter, W., Andries, K., Pojer, F., Dyson, P. J., & Cole, S. T. (2014). Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Molecular Medicine, 6(3), 372–383. https://doi.org/10.1002/EMMM.201303575
   PubMed Web of Science ®Google Scholar
• Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., Milano, A., De Rossi, E., Belanova, M., Bobovska, A., Dianiskova, P., Kordulakova, J., Sala, C., Fullam, E., Schneider, P., … Cole, S. T. (2009). Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science (New York, N.Y.), 324(5928), 801–804. https://doi.org/10.1126/SCIENCE.1171583
   PubMed Web of Science ®Google Scholar
• Makarov, V., Neres, J., Hartkoorn, R. C., Ryabova, O. B., Kazakova, E., Šarkan, M., Huszár, S., Piton, J., Kolly, G. S., Vocat, A., Conroy, T. M., Mikušová, K., & Cole, S. T. (2015). The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 59(8), 4446–4452. https://doi.org/10.1128/AAC.00778-15
   PubMed Web of Science ®Google Scholar
• Manina, G. R., Pasca, M., Buroni, S., De Rossi, E., & Riccardi, G. (2010). Decaprenylphosphoryl-β-D-ribose 2’-epimerase from Mycobacterium tuberculosis is a magic drug target. Current Medicinal Chemistry, 17(27), 3099–3108. https://doi.org/10.2174/092986710791959693
   PubMed Web of Science ®Google Scholar
• Manjunatha, M. R., Shandil, R., Panda, M., Sadler, C., Ambady, A., Panduga, V., Kumar, N., Mahadevaswamy, J., Sreenivasaiah, M., Narayan, A., Guptha, S., Sharma, S., Sambandamurthy, V. K., Ramachandran, V., Mallya, M., Cooper, C., Mdluli, K., Butler, S., Tommasi, R., … Shirude, P. S. (2019). Scaffold morphing to identify novel DprE1 inhibitors with antimycobacterial activity. ACS Medicinal Chemistry Letters, 10(10), 1480–1485. https://doi.org/10.1021/acsmedchemlett.9b00343
   PubMed Web of Science ®Google Scholar
• Miku.sova, K., Makarov, V., & Neres, J. (2014). DprE1–from the discovery to the promising tuberculosis drug target. Current Pharmaceutical Design, 20(27), 4379–4403. https://doi.org/10.2174/138161282027140630122724
   PubMed Web of Science ®Google Scholar
• Mikušová, K., & Ekins, S. (2017). Learning from the past for TB drug discovery in the future. Drug Discovery Today, 22(3), 534–545. https://doi.org/10.1016/J.DRUDIS.2016.09.025
   PubMed Web of Science ®Google Scholar
• Naik, M., Humnabadkar, V., Tantry, S. J., Panda, M., Narayan, A., Guptha, S., Panduga, V., Manjrekar, P., Jena, L. K., Koushik, K., Shanbhag, G., Jatheendranath, S., Manjunatha, M. R., Gorai, G., Bathula, C., Rudrapatna, S., Achar, V., Sharma, S., Ambady, A., … Ghorpade, S. R. (2014). 4-Aminoquinolone piperidine amides: Noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity. Journal of Medicinal Chemistry, 57(12), 5419–5434. https://doi.org/10.1021/jm5005978
   PubMed Web of Science ®Google Scholar
• Neres, J., Hartkoorn, R. C., Chiarelli, L. R., Gadupudi, R., Pasca, M. R., Mori, G., Venturelli, A., Savina, S., Makarov, V., Kolly, G. S., Molteni, E., Binda, C., Dhar, N., Ferrari, S., Brodin, P., Delorme, V., Landry, V., de Jesus Lopes Ribeiro, A. L., Farina, D., … Cole, S. T. (2015). 2-carboxyquinoxalines kill Mycobacterium tuberculosis through noncovalent inhibition of DprE1. ACS Chemical Biology, 10(3), 705–714. https://doi.org/10.1021/cb5007163
   PubMed Web of Science ®Google Scholar
• Neres, J., Pojer, F., Molteni, E., Chiarelli, L. R., Dhar, N., Boy-Röttger, S., Buroni, S., Fullam, E., Degiacomi, G., Lucarelli, A. P., Read, R. J., Zanoni, G., Edmondson, D. E., De Rossi, E., Pasca, M. R., McKinney, J. D., Dyson, P. J., Riccardi, G., Mattevi, A., Cole, S. T., & Binda, C. (2012). Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Science Translational Medicine, 4(150), 150ra121. https://doi.org/10.1126/SCITRANSLMED.3004395
   PubMed Web of Science ®Google Scholar
• OPC-167832 | Working Group for New TB Drugs. (n.d). Retrieved February 27, 2022, from https://www.newtbdrugs.org/pipeline/compound/opc-167832
   Google Scholar
• Panda, M., Ramachandran, S., Ramachandran, V., Shirude, P. S., Humnabadkar, V., Nagalapur, K., Sharma, S., Kaur, P., Guptha, S., Narayan, A., Mahadevaswamy, J., Ambady, A., Hegde, N., Rudrapatna, S. S., Hosagrahara, V. P., Sambandamurthy, V. K., & Raichurkar, A. (2014). Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. Journal of Medicinal Chemistry, 57(11), 4761–4771. https://doi.org/10.1021/jm5002937
   PubMed Web of Science ®Google Scholar
• Peng, C. T., Gao, C., Wang, N. Y., You, X. Y., Zhang, L. D., Zhu, Y. X., Xv, Y., Zuo, W. Q., Ran, K., Deng, H. X., Lei, Q., Xiao, K. J., & Yu, L. T. (2015). Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1,3-benzothiazin-4-one derivatives. Bioorganic & Medicinal Chemistry Letters, 25(7), 1373–1376. https://doi.org/10.1016/j.bmcl.2015.02.061
   PubMed Web of Science ®Google Scholar
• Pipeline | Working Group for New TB Drugs. (n.d). Retrieved November 14, 2021, from https://www.newtbdrugs.org/pipeline/clinical
   Google Scholar
• Piton, J., Foo, C. S. Y., & Cole, S. T. (2017). Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors. Drug Discovery Today, 22(3), 526–533. https://doi.org/10.1016/J.DRUDIS.2016.09.014
   PubMed Web of Science ®Google Scholar
• Piton, J., Vocat, A., Lupien, A., Foo, C. S., Riabov, O., Makarov, V., & Cole, S. T. (2018). Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 62(10), e00681-18.https://doi.org/10.1128/AAC.00681-18/SUPPL_FILE/ZAC010187478S1.PDF
   PubMed Web of Science ®Google Scholar
• Purohit, V., & Basu, A. K. (2000). Mutagenicity of nitroaromatic compounds. Chemical Research in Toxicology, 13(8), 673–692. https://doi.org/10.1021/TX000002X
   PubMed Web of Science ®Google Scholar
• Qin, R., Wang, P., Wang, B., Fu, L., Batt, S. M., Besra, G. S., Wu, C., Wang, Y., Huang, H., Lu, Y., & Li, G. (2022). Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis. European Journal of Medicinal Chemistry, 231, 114145. https://doi.org/10.1016/J.EJMECH.2022.114145
   PubMed Web of Science ®Google Scholar
• Ramírez-Lapausa, M., Menéndez-Saldaña, A., & Noguerado-Asensio, A. (2015). [Extrapulmonary tuberculosis]. Revista Espanola de Sanidad Penitenciaria, 17(1), 3–11. https://doi.org/10.4321/S1575-06202015000100002
   PubMedGoogle Scholar
• Riccardi, G., Pasca, M. R., Chiarelli, L. R., Manina, G., Mattevi, A., & Binda, C. (2013). The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. Applied Microbiology and Biotechnology, 97(20), 8841–8848. https://doi.org/10.1007/S00253-013-5218-X
   PubMed Web of Science ®Google Scholar
• Richter, A., Narula, G., Rudolph, I., Seidel, R. W., Wagner, C., Av-Gay, Y., & Imming, P. (2022). Efficient synthesis of benzothiazinone analogues with activity against intracellular Mycobacterium tuberculosis. ChemMedChem, 17(6), e202100733. https://doi.org/10.1002/CMDC.202100733
   PubMed Web of Science ®Google Scholar
• Richter, A., Seidel, R. W., Goddard, R., Eckhardt, T., Lehmann, C., Dörner, J., Siersleben, F., Sondermann, T., Mann, L., Patzer, M., Jäger, C., Reiling, N., & Imming, P. (2022). BTZ-derived benzisothiazolinones with in vitro activity against Mycobacterium tuberculosis. ACS Medicinal Chemistry Letters, 13(8), 1302–1310. https://doi.org/10.1021/ACSMEDCHEMLETT.2C00215/SUPPL_FILE/ML2C00215_SI_011.XYZ
   PubMed Web of Science ®Google Scholar
• Sahoo, S. K., Ahmad, M. N., Kaul, G., Nanduri, S., Dasgupta, A., Chopra, S., & Yaddanapudi, V. M. (2022). Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy. RSC Medicinal Chemistry, 13(5), 585–593. https://doi.org/10.1039/D1MD00387A
   PubMedGoogle Scholar
• Sahoo, S. K., Gajula, S. N. R., Ahmad, M. N., Kaul, G., Nanduri, S., Sonti, R., Dasgupta, A., Chopra, S., & Yaddanapudi, V. M. (2022). Bioevaluation of quinoline-4-carbonyl derivatives of piperazinyl-benzothiazinones as promising antimycobacterial agents. Archiv Der Pharmazie, 355(11), 2200168. https://doi.org/10.1002/ardp.202200168
   Web of Science ®Google Scholar
• Sammartino, J. C., Morici, M., Stelitano, G., Degiacomi, G., Riccardi, G., & Chiarelli, L. R. (2022). Functional investigation of the antitubercular drug target Decaprenylphosphoryl-β-D-ribofuranose-2-epimerase DprE1/DprE2 complex. Biochemical and Biophysical Research Communications, 607, 49–53. https://doi.org/10.1016/J.BBRC.2022.03.091
   PubMed Web of Science ®Google Scholar
• Seung, K. J., Keshavjee, S., & Rich, M. L. (n.d). Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. https://doi.org/10.1101/cshperspect.a017863
   Google Scholar
• Shaku, M., Ealand, C., & Kana, B. D. (2020). Cell surface biosynthesis and remodeling pathways in mycobacteria reveal new drug targets. Frontiers in Cellular and Infection Microbiology, 10, 603382. https://doi.org/10.3389/FCIMB.2020.603382/BIBTEX
   PubMed Web of Science ®Google Scholar
• Shetye, G. S., Franzblau, S. G., & Cho, S. (2020). New tuberculosis drug targets, their inhibitors, and potential therapeutic impact. Translational Research: The Journal of Laboratory and Clinical Medicine, 220, 68–97. https://doi.org/10.1016/J.TRSL.2020.03.007
   PubMed Web of Science ®Google Scholar
• Shi, R., Wang, B., Stelitano, G., Wu, X., Shan, Y., Wu, Y., Wang, X., Chiarelli, L. R., Lu, Y., & Qiao, C. (2022). Development of 6-methanesulfonyl-8-nitrobenzothiazinone Based Antitubercular Agents. ACS Medicinal Chemistry Letters, 13(4), 593–598. https://doi.org/10.1021/ACSMEDCHEMLETT.1C00652/SUPPL_FILE/ML1C00652_SI_002.PDF
   PubMed Web of Science ®Google Scholar
• Shirude, P. S., Shandil, R. K., Manjunatha, M. R., Sadler, C., Panda, M., Panduga, V., Reddy, J., Saralaya, R., Nanduri, R., Ambady, A., Ravishankar, S., Sambandamurthy, V. K., Humnabadkar, V., Jena, L. K., Suresh, R. S., Srivastava, A., Prabhakar, K. R., Whiteaker, J., McLaughlin, R. E., … Chatterji, M. (2014). Lead optimization of 1,4-azaindoles as antimycobacterial agents. Journal of Medicinal Chemistry, 57(13), 5728–5737. https://doi.org/10.1021/jm500571f
   PubMed Web of Science ®Google Scholar
• Shirude, P. S., Shandil, R., Sadler, C., Naik, M., Hosagrahara, V., Hameed, S., Shinde, V., Bathula, C., Humnabadkar, V., Kumar, N., Reddy, J., Panduga, V., Sharma, S., Ambady, A., Hegde, N., Whiteaker, J., McLaughlin, R. E., Gardner, H., Madhavapeddi, P., … Chatterji, M. (2013). Azaindoles: Noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. Journal of Medicinal Chemistry, 56(23), 9701–9708. https://doi.org/10.1021/JM401382V
   PubMed Web of Science ®Google Scholar
• Sotgiu, G., Centis, R., D'ambrosio, L., & Migliori, G. B. (2015). Tuberculosis treatment and drug regimens. Cold Spring Harbor Perspectives in Medicine, 5(5), a017822. https://doi.org/10.1101/CSHPERSPECT.A017822
   PubMed Web of Science ®Google Scholar
• Stephanie, F., Saragih, M., & Tambunan, U. S. F. (2021). Recent progress and challenges for drug-resistant tuberculosis treatment. Pharmaceutics, 13(5), 592. https://doi.org/10.3390/pharmaceutics13050592
   PubMed Web of Science ®Google Scholar
• TBA-7371 | Working Group for New TB Drugs. (n.d). Retrieved February 27, 2022, from https://www.newtbdrugs.org/pipeline/compound/tba-7371
   Google Scholar
• Tiwari, R., Miller, P. A., Chiarelli, L. R., Mori, G., Šarkan, M., Centárová, I., Cho, S., Mikušová, K., Franzblau, S. G., Oliver, A. G., & Miller, M. J. (2016). Design, syntheses, and anti-TB activity of 1,3-benzothiazinone azide and click chemistry products inspired by BTZ043. ACS Medicinal Chemistry Letters, 7(3), 266–270. https://doi.org/10.1021/acsmedchemlett.5b00424
   PubMed Web of Science ®Google Scholar
• Tiwari, R., Miller, P. A., Cho, S., Franzblau, S. G., & Miller, M. J. (2015). Syntheses and antituberculosis activity of 1,3-benzothiazinone sulfoxide and sulfone derived from BTZ043. ACS Medicinal Chemistry Letters, 6(2), 128–133. https://doi.org/10.1021/ML5003458
   PubMed Web of Science ®Google Scholar
• Tornheim, J. A., & Dooley, K. E. (2019). The global landscape of tuberculosis therapeutics. Annual Review of Medicine, 70, 105–120. https://doi.org/10.1146/annurev-med-040717-051150
   PubMed Web of Science ®Google Scholar
• Trefzer, C., Škovierová, H., Buroni, S., Bobovská, A., Nenci, S., Molteni, E., Pojer, F., Pasca, M. R., Makarov, V., Cole, S. T., Riccardi, G., Mikušová, K., & Johnsson, K. (2012). Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2’-oxidase DprE1. Journal of the American Chemical Society, 134(2), 912–915. https://doi.org/10.1021/JA211042R
   PubMed Web of Science ®Google Scholar
• Umare, M. D., Khedekar, P. B., & Chikhale, R. V. (2021). Mycobacterial membrane protein large 3 (MmpL3) inhibitors: A promising approach to combat tuberculosis. ChemMedChem. 16(20), 3136–3148. https://doi.org/10.1002/CMDC.202100359
   PubMed Web of Science ®Google Scholar
• Valencia, J., Rubio, V., Puerto, G., Vasquez, L., Bernal, A., Mora, J. R., Cuesta, S. A., Paz, J. L., Insuasty, B., Abonia, R., Quiroga, J., Insuasty, A., Coneo, A., Vidal, O., Márquez, E., & Insuasty, D. (2022). QSAR studies, molecular docking, molecular dynamics, synthesis, and biological evaluation of novel quinolinone-based thiosemicarbazones against Mycobacterium tuberculosis. Antibiotics, 12(1), 61. https://doi.org/10.3390/antibiotics12010061
   Google Scholar
• Velayati, A. A., Farnia, P., & Masjedi, M. R. (2013). The totally drug resistant tuberculosis (TDR-TB). International Journal of Clinical and Experimental Medicine, 6(4), 307. /pmc/articles/PMC3631557/
   PubMed Web of Science ®Google Scholar
• Wang, P., Batt, S. M., Wang, B., Fu, L., Qin, R., Lu, Y., Li, G., Besra, G. S., & Huang, H. (2021). Discovery of novel thiophene-arylamide derivatives as DprE1 inhibitors with potent antimycobacterial activities. Journal of Medicinal Chemistry, 64(9), 6241–6261. https://doi.org/10.1021/acs.jmedchem.1c00263
   PubMed Web of Science ®Google Scholar
• Wang, A. A., Lu, Y., Lv, K., Ma, C., Xu, S., Wang, B., Wang, A. A., Xia, G., & Liu, M. (2020). Design, synthesis and antimycobacterial activity of new benzothiazinones inspired by rifampicin/rifapentine. Bioorganic Chemistry, 102, 104135. https://doi.org/10.1016/J.BIOORG.2020.104135
   PubMed Web of Science ®Google Scholar
• Wang, H., Lv, K., Li, X., Wang, B. B., Wang, A., Tao, Z., Geng, Y., Wang, B. B., Huang, M., Liu, M., Guo, H., & Lu, Y. (2019). Design, synthesis and antimycobacterial activity of novel nitrobenzamide derivatives. Chinese Chemical Letters, 30(2), 413–416. https://doi.org/10.1016/j.cclet.2018.08.005
   Web of Science ®Google Scholar
• Wang, A., Lv, K., Tao, Z., Gu, J., Fu, L., Liu, M., Wan, B., Franzblau, S. G., Ma, C., Ma, X., Han, B., Wang, A., Xu, S., & Lu, Y. (2019). Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents. European Journal of Medicinal Chemistry, 181, 111595. https://doi.org/10.1016/J.EJMECH.2019.111595
   PubMed Web of Science ®Google Scholar
• Wang, A., Ma, C., Chai, Y., Liu, X., Lv, K., Fu, L., Wang, B., Jia, X., Liu, M., & Lu, Y. (2020). Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents. European Journal of Medicinal Chemistry, 200, 112409. https://doi.org/10.1016/J.EJMECH.2020.112409
   PubMed Web of Science ®Google Scholar
• Wang, F., Sambandan, D., Halder, R., Wang, J., Batt, S. M., Weinrick, B., Ahmad, I., Yang, P., Zhang, Y., Kim, J., Hassani, M., Huszar, S., Trefzer, C., Ma, Z., Kaneko, T., Mdluli, K. E., Franzblau, S., Chatterjee, A. K., Johnsson, K., … Schultz, P. G. (2013). Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proceedings of the National Academy of Sciences, 110(27), E2510-E2517. https://doi.org/10.1073/pnas.1309171110
   Web of Science ®Google Scholar
• Wang, A. A., Xu, S., Chai, Y., Xia, G., Wang, B., Lv, K., Ma, C., Wang, D., Wang, A. A., Qin, X., Liu, M., & Lu, Y. (2021). Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 218, 113398. https://doi.org/10.1016/J.EJMECH.2021.113398
   PubMed Web of Science ®Google Scholar
• Whitehurst, B. C., Young, R. J., Burley, G. A., Cacho, M., Torres, P., & Vela-Gonzalez del Peral, L. (2020). Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors). Bioorganic & Medicinal Chemistry Letters, 30(12), 127192. https://pubmed.ncbi.nlm.nih.gov/32312582/ https://doi.org/10.1016/j.bmcl.2020.127192
   PubMed Web of Science ®Google Scholar
• Xavier, A. S., & Lakshmanan, M. (2014). Delamanid: A new armor in combating drug-resistant tuberculosis. Journal of Pharmacology & Pharmacotherapeutics, 5(3), 222–224. https://doi.org/10.4103/0976-500X.136121
   PubMedGoogle Scholar
• Xiong, L., Gao, C., Shi, Y. J., Tao, X., Rong, J., Liu, K. L., Peng, C. T., Wang, N. Y., Lei, Q., Zhang, Y. W., Yu, L. T., & Wei, Y. Q. (2018). Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles. RSC Advances, 8(20), 11163–11176. https://doi.org/10.1039/C8RA00720A
   PubMed Web of Science ®Google Scholar
• Yadav, S., Soni, A., Tanwar, O., Bhadane, R., Besra, G. S., & Kawathekar, N. (2023). The DprE1 inhibitors: Enduring aspirations for future anti-TB drug discovery. ChemMedChem, e202300099,1-32.https://doi.org/10.1002/cmdc.202300099
   PubMed Web of Science ®Google Scholar
• Yalcin-Ozkat, G., Ersan, R. H., Ulger, M., Ulger, S. T., Burmaoglu, S., Yildiz, I., & Algul, O. (2023). Design, synthesis, and computational studies of benzimidazole derivatives as new antitubercular agents. Journal of Biomolecular Structure and Dynamics, 41(7), 2667–2686. https://doi.org/10.1080/07391102.2022.2036241
   PubMed Web of Science ®Google Scholar
• Yang, H., & Lu, S. (2020). COVID-19 and tuberculosis. Journal of Translational Internal Medicine, 8(2), 59–65. https://doi.org/10.2478/JTIM-2020-0010
   PubMed Web of Science ®Google Scholar
• Zhanel, G. G., Love, R., Adam, H., Golden, A., Zelenitsky, S., Schweizer, F., Gorityala, B., Lagacé-Wiens, P. R. S., Rubinstein, E., Walkty, A., Gin, A. S., Gilmour, M., Hoban, D. J., Lynch, J. P., & Karlowsky, J. A. (2015). Tedizolid: A novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs, 75(3), 253–270. https://doi.org/10.1007/S40265-015-0352-7
   PubMed Web of Science ®Google Scholar
• Zhang, G., Howe, M., & Aldrich, C. C. (2019). Spirocyclic and bicyclic 8-nitrobenzothiazinones for tuberculosis with improved physicochemical and pharmacokinetic properties. ACS Medicinal Chemistry Letters, 10(3), 348–351. https://doi.org/10.1021/ACSMEDCHEMLETT.8B00634/ASSET/IMAGES/MEDIUM/ML-2018-00634C_0006.GIF
   PubMed Web of Science ®Google Scholar
• Zhang, R., Lv, K., Wang, B., Li, L., Wang, B., Liu, M., Guo, H., Wang, A., & Lu, Y. (2017). Design, synthesis and antitubercular evaluation of benzothiazinones containing an oximido or amino nitrogen heterocycle moiety. RSC Advances, 7(3), 1480–1483. https://doi.org/10.1039/C6RA25712G
   Web of Science ®Google Scholar
• Zhang, G., Sheng, L., Hegde, P., Li, Y., & Aldrich, C. C. (2021). 8-cyanobenzothiazinone analogs with potent antitubercular activity. Medicinal Chemistry Research: An International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents, 30(2), 449–458. https://doi.org/10.1007/S00044-020-02676-4
   PubMed Web of Science ®Google Scholar
• Zumla, A., Chakaya, J., Centis, R., D'Ambrosio, L., Mwaba, P., Bates, M., Kapata, N., Nyirenda, T., Chanda, D., Mfinanga, S., Hoelscher, M., Maeurer, M., & Migliori, G. B. (2015). Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies. The Lancet. Respiratory Medicine, 3(3), 220–234. https://doi.org/10.1016/S2213-2600(15)00063-6
   PubMed Web of Science ®Google Scholar